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Abstract
Influenza is thought to be communicated from person to person by multiple pathways. However, the relative importance of
different routes of influenza transmission is unclear. To better understand the potential for the airborne spread of influenza,
we measured the amount and size of aerosol particles containing influenza virus that were produced by coughing. Subjects
were recruited from patients presenting at a student health clinic with influenza-like symptoms. Nasopharyngeal swabs
were collected from the volunteers and they were asked to cough three times into a spirometer. After each cough, the
cough-generated aerosol was collected using a NIOSH two-stage bioaerosol cyclone sampler or an SKC BioSampler. The
amount of influenza viral RNA contained in the samplers was analyzed using quantitative real-time reverse-transcription PCR
(qPCR) targeting the matrix gene M1. For half of the subjects, viral plaque assays were performed on the nasopharyngeal
swabs and cough aerosol samples to determine if viable virus was present. Fifty-eight subjects were tested, of whom 47
were positive for influenza virus by qPCR. Influenza viral RNA was detected in coughs from 38 of these subjects (81%).
Thirty-five percent of the influenza RNA was contained in particles .4 mm in aerodynamic diameter, while 23% was in
particles 1 to 4 mm and 42% in particles ,1 mm. Viable influenza virus was detected in the cough aerosols from 2 of 21
subjects with influenza. These results show that coughing by influenza patients emits aerosol particles containing influenza
virus and that much of the viral RNA is contained within particles in the respirable size range. The results support the idea
that the airborne route may be a pathway for influenza transmission, especially in the immediate vicinity of an influenza
patient. Further research is needed on the viability of airborne influenza viruses and the risk of transmission.
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Introduction
Influenza continues to be a major public health concern because
of the substantial health burden from seasonal influenza and the
potential for a severe pandemic. Although influenza is known to be
transmitted by infectious secretions, these secretions can be
transferred from person to person in many different ways, and
the relative importance of the different pathways is not known.
The likelihood of the airborne transmission of influenza virus by
infectious aerosols is particularly unclear, with some investigators
concluding that airborne transmission is a key route (reviewed in
[1,2,3]), while others maintain that it rarely, if ever, occurs
(reviewed in [4]). The question of airborne transmission is
especially important in healthcare facilities, where influenza
patients tend to congregate during influenza season, because it
directly impacts the infection control and personal protective
measures that should be taken by healthcare workers. During the
2009 H1N1 pandemic, for example, a United States Institute of
Medicine (IOM) panel recommended that healthcare workers in
close contact with influenza patients wear respirators to avoid
infectious aerosols [5]. This recommendation was subsequently
adopted by some health authorities such as the US Centers for
Disease Control and Prevention (CDC), but not by others, such as
the World Health Organization (WHO). The IOM panel also
noted that many questions about the airborne transmission of
influenza are unresolved, and the issue remains controversial.
The probability of the airborne transmission of influenza virus
depends in part on the amount of aerosolized virus to which
people are exposed. Two recent studies have measured the
amount of airborne influenza viral RNA in healthcare facilities
during the influenza season [6,7]. Both studies found that the
highest concentrations of influenza RNA were detected in
locations where, and during times when, the number of influenza
patients was highest. The studies also found that 42 to 53% of the
influenza viral RNA was contained in airborne particles less than
4 mm in aerodynamic diameter (the respirable size fraction).
Aerosol particles in this size range are of particular concern
because they can remain airborne for an extended time and
because they can be drawn down into the alveolar region of the
lungs during inhalation. The infectious dose required for
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transmission is unclear, but two reviews of previous studies
concluded that the infectious dose by the aerosol route is likely
considerably lower than the infectious dose by intranasal
inoculation [2,8], and that aerosol inoculation results in more
severe symptoms [8], presumably because aerosol particles are
able to deposit deeper in the respiratory tract. However, the
viability of influenza viruses in particles of different sizes and the
persistence of viable airborne virus in the environment are not yet
known.
A few studies have examined airborne influenza virus
production at the source (influenza patients). Fabian et al. [9]
and Stelzer-Braid et al. [10] detected influenza viral RNA
produced by influenza patients during breathing and talking.
Fabian et al. [9] showed that 60% of patients with influenza A and
14% of patients with influenza B had detectable levels of viral
RNA in their exhaled breath; they also reported that over 87% of
the exhaled particles were less than 1 mm in diameter. Milton et al.
[11] collected aerosol particles exhaled by influenza patients and
found that patients shed about 33 viral copies/minute in aerosol
particles $5 mm and 187 viral copies/minute in particles ,5 mm.
They also showed that surgical masks substantially reduced
particle release (especially for large particles), and found culturable
virus in the breath from two subjects. Despite these studies,
however, little is known about the production of potentially
infectious aerosols by influenza patients.
The purpose of this study was to measure the amount and size
of airborne particles containing influenza virus that are produced
by patients when they cough. A better understanding of the
amount of potentially infectious material released by patients and
the size of the particles carrying the virus will assist in determining
the possible role of airborne transmission in the spread of influenza
and in devising measures to prevent it.
Results
Fifty-eight volunteer subjects (38 male, 20 female, ages 18 to 33)
participated in the study during October-November 2009, when
the pandemic influenza A (H1N1) virus predominated. Seven
subjects reported receiving a seasonal influenza vaccination; none
had received a vaccination against the 2009 H1N1 influenza virus.
At the clinic, the rapid influenza tests from 7 subjects were
positive. In subsequent testing, influenza viral RNA was detected
by quantitative real-time reverse-transcription PCR (qPCR) in
nasopharyngeal swabs from 43 of 56 subjects, with a median viral
copy number of 51 per sample (SD 161 after the exclusion of one
outlying value of 3727), where each sample consisted of two swabs
collected from each patient. Viral plaque assays (VPA) were
performed on nasopharyngeal swabs from 30 subjects. Viable
influenza virus was detected in 11 of these VPA’s (median
6.0610
4 pfu/ml, SD 2.85610
5). Nasopharyngeal swabs from two
subjects were not tested using qPCR but were positive by rapid test
and VPA. For two other subjects, influenza virus was not detected
in the nasopharyngeal swabs by qPCR or rapid test, but was
subsequently detected in their cough aerosols by qPCR. Overall,
influenza virus was detected in 47 of the 58 subjects. A flowchart
showing the subjects and the results of the tests performed to detect
influenza is presented in Figure 1.
Because results from the VPA and qPCR assays were not
available until several days after patients were tested, cough-
generated aerosols were collected from all patients and their
influenza status was determined afterwards. Cough-generated
aerosols were collected from 48 subjects using the NIOSH two-
stage aerosol sampler, 38 of whom were later found to be
influenza-positive as described above. Influenza viral RNA was
detected in at least one sampler stage for 32 of the 38 influenza-
positive subjects. The amount of influenza viral RNA expelled by
each patient during coughing is shown in Figure 2, while the
median number of viral particle copies per cough and the
distribution of the viral RNA by particle size for these subjects are
shown in Table 1. Sixty-five percent of the influenza viral RNA
was found in particles less than 4 mm in diameter. VPA’s were
performed on cough aerosols collected from 20 subjects using the
NIOSH sampler, 12 of whom were influenza-positive. One of
these cough aerosol VPA’s was positive, with 0.8 pfu/ml per
cough found in the first tube. This sample was from the patient
with the third-highest cough aerosol viral particle count by qPCR
(83 viral copies per cough). A summary of the VPA results for the
NIOSH and SKC samplers is shown in Table 2.
The SKC BioSampler was used to collect cough aerosols from
10 subjects, 9 of whom were influenza-positive. Influenza viral
RNA was detected in 6 of the cough aerosol samples by qPCR
(median copy number per cough 30, SD 70, excluding 1 sample
with 355 viral copies per cough). Viable influenza virus was found
in 1 of these cough aerosol samples; 5 pfu/ml per cough were
detected in this sample by VPA and 10 viral particles per cough
were detected using qPCR.
The oral temperature, self-reported symptoms, cough volumes,
and peak cough flow rates of all subjects are shown in Table 3.
Influenza-positive subjects reported more symptoms overall than
influenza-negative subjects, but there was no clear relationship
between any of the clinical parameters and the amount of
influenza RNA contained in the cough-generated aerosols. The
complete set of experimental data for this paper is available online
as supplemental material (Results S1).
Discussion
The production and release of potentially infectious aerosol
particles by influenza patients is a major concern because of the
possibility that these particles could transmit the disease to
healthcare providers and to other patients. However, little is
known about the amount, size distribution and viability of the
influenza virus-laden particles generated by these patients when
they cough. Our study found that 81% of the influenza-positive
patients had detectable levels of influenza viral RNA in their
cough aerosols. Further, 65% of the influenza viral RNA was
contained in particles in the respirable size fraction (,4 mm).
These are particles that are small enough to remain airborne for
an extended time and to be inhaled into the alveolar region of the
lungs. Particles in this size fraction are of particular concern
because some human experiments have suggested that a much
smaller dose of influenza virus is needed to initiate an infection
when it is deposited in the alveolar region compared to intranasal
inoculation [8]. It is interesting to note that the fraction of
influenza RNA-laden particles in the respirable size range was
somewhat higher in this study than the 42 to 53% that was found
during aerosol sampling in healthcare facilities [6,7]. This may in
part reflect a loss of large particles in the cough aerosol collection
system, and may also be due to the natural coagulation of aerosol
particles that occurs over time.
A comparison of the amount of influenza viral RNA in the
nasopharyngeal swabs and the cough-generated aerosols found a
correlation coefficient of r=0.73 for the NIOSH sampler and 0.85
for the SKC BioSampler (in both cases, excluding one outlying
point). This suggests that, as might be expected, patients with
higher viral loads in their nasopharyngeal region generally shed
more viral RNA during coughing. It is especially interesting to
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varied widely from patient to patient; in fact, 45% of the influenza
viral RNA from cough aerosols collected using the NIOSH
sampler came from just 4 of 38 subjects with influenza. Large
variations in the amount of virus in cough aerosols are not
surprising, since influenza viral shedding varies significantly from
patient to patient and over the course of the illness [12], and since
previous studies have shown that some individuals shed much
greater quantities of aerosol particles during breathing and
coughing than do others [13]. However, this does suggest that
some influenza patients might be able to serve as ‘‘superspreaders’’
who are considerably more likely than other patients to transmit
the disease by the airborne route [14].
We were able to show that viable influenza virus was present in
the cough-generated aerosols from 2 of 11 subjects for whom
viable virus was found in their nasopharyngeal swabs. This
demonstrates that, at least in some cases, influenza patients do
release airborne particles containing potentially infectious virus.
This result supports the theory that airborne transmission of
influenza is possible, although additional factors such as the
survival time and infectivity of the airborne virus remain unclear.
It is important to note, however, that our results are almost
certainly an underestimate of the amount of viable airborne virus
that is released. It is known that the process of collecting aerosols
frequently leads to inactivation of viruses [15,16]. The NIOSH
two-stage sampler collects particles in dry tubes and on a filter,
which can damage delicate viruses by desiccation or mechanical
damage. The SKC BioSampler collects particles in liquid, which
helps preserve viability, but it does not collect small particles
efficiently and is not size-selective. In laboratory experiments
collecting aerosolized influenza virus, the viability of virus
collected with an SKC BioSampler was about 4 times higher
than the viability of virus collected with the NIOSH sampler [17].
In addition, viral plaque assays are widely used to study virus
viability, but they are not sensitive enough to detect small
quantities of virus. Better aerosol collection methods and more
sensitive viability assays may lead to higher estimates of the
amount of viable airborne virus released by people with influenza.
Finally, two limitations in our study should be noted. First,
studies of cough-generated aerosols have shown that human
coughs produce a tremendous range of particle sizes, ranging from
less than 100 nm to visible drops larger than a millimeter
[18,19,20,21]. Large aerosol particles settle much more quickly
than do small particles, and are also more likely to impact and stick
Figure 1. Flow chart showing patients and tests performed. The numbers in parentheses are the number of aerosol samples collected using
SKC BioSamplers and NIOSH aerosol samplers.
doi:10.1371/journal.pone.0015100.g001
Airborne Influenza Virus from Human Coughs
PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15100to surfaces. Our cough aerosol collection system collects small
particles, but many larger particles are almost certainly lost. Thus,
the collection system should provide a good representation of the
amount of virus contained in aerosol particles capable of
remaining airborne for several minutes or longer, but it does not
collect the total amount of viral material expelled by a coughing
patient. Second, all of the patients who participated in our study
were young otherwise healthy adults who were ambulatory and
able to be treated in an outpatient clinic. Patients who are more
severely ill would be expected to have higher viral loads and more
respiratory fluids in the lungs [22], which could increase the
amount of virus in the cough-generated aerosols. In addition,
influenza virus shedding peaks early in the course of the illness
(typically about 2 days after the onset of symptoms [12]). In our
study, 40% of subjects with influenza reported that 3 days or more
had passed since the onset of their symptoms. Thus, many had
likely passed the peak of viral shedding by the time they entered
the study.
In conclusion, our study measured the amount and size
distribution of aerosol particles containing influenza viral RNA
that were produced by influenza patients as they coughed. Our
results show that influenza patients do produce aerosol particles
containing measurable amounts of influenza virus while coughing.
Further, much of the viral RNA is contained within particles that
can remain airborne for an extended time and that can enter the
alveolar region of the lungs if they are inhaled. Our study was also
able to demonstrate that at least some influenza patients expelled
airborne particles containing viable influenza virus. Our results
support the idea that airborne transmission may play a role in the
spread of influenza, especially in the immediate vicinity of an
influenza patient.
Materials and Methods
Ethics Statement
All procedures involving human subjects were reviewed and
approved by the National Institute for Occupational Safety and
Health (NIOSH) and West Virginia University (WVU) Institu-
tional Review Boards. Written informed consent was obtained
from all study participants.
Volunteer subjects were recruited from patients presenting with
influenza-like symptoms at the student health clinic of WVU in
Morgantown, West Virginia, USA, during October and Novem-
ber of 2009. After providing informed consent, each subject was
given a rapid influenza test (QuickVue Influenza A+B test,
Quidel). The rapid test was used to provide an initial estimate of
influenza case numbers; however, because the sensitivity of the test
was reported to be low [23], subjects were allowed to continue
participating in the study regardless of the outcome. Two
nasopharyngeal mucus swabs were collected for analysis by qPCR
and viral plaque assay (VPA), the subject’s oral temperature was
taken, and the subject was asked to answer a brief health
questionnaire.
Cough-generated aerosols from the volunteer subjects were
collected using the cough aerosol particle collection system
(Figure 3) similar to that described previously [24]. The system
consisted of an ultrasonic spirometer (Easy One, NDD Medical
Technologies) and a 10 liter piston-style spirometer (SensorMedics
model 762609) modified to allow aerosol collection using a
NIOSH two-stage cyclone aerosol sampler [6] or an SKC
BioSampler with a 5 ml collection vessel (#225-9593, SKC).
The NIOSH sampler collected cough aerosol particles in a 15 ml
centrifuge tube (stage 1; #35-2096, Falcon), a 1.5 ml centrifuge
tube (stage 2; #02-681-339, Fisher Scientific) and a 37 mm
polytetrafluoroethylene (PTFE) filter with 2 mm pores (#225-27-
07, SKC). The NIOSH sampler conforms to the ACGIH/ISO
Table 1. Influenza viral RNA detected in the NIOSH two-stage aerosol sampler.
Aerosol particle size range
(aerodynamic diameter)
Median # of viral
copies per cough
% of viral RNA contained
in particles in this size range
% of subjects whose cough aerosol contained
viral RNA-laden particles in this size range
.4 mm 6.3 (SD 9.0) 35% 90%
1t o4mm 3.3 (SD 6.9) 23% 81%
,1 mm 3.7 (SD 23.7) 42% 75%
All particles 15.8 (SD 29.3) 100% 100%
The NIOSH two-stage sampler was used to collect cough aerosols from 48 subjects, 38 of whom were later confirmed to have influenza. Influenza viral RNA was
detected in at least one sampler stage for 32 of the viral positive subjects (84%). This table shows the viral copy number and distribution of particle sizes for the 32
subjects for whom influenza viral RNA was detected in their cough-generated aerosol particles. As illustrated by the large standard deviations (SD), the amount of
influenza viral RNA in the cough aerosols varied tremendously between patients.
doi:10.1371/journal.pone.0015100.t001
Figure 2. Influenza viral RNA collected from coughs using the
NIOSH two-stage aerosol sampler. Influenza viral RNA was
detected in the cough aerosols from 32 of 38 influenza-positive
patients. This plot shows the number of viral copies per cough detected
in aerosol particles collected in sampler tube 1 (.4 mm), tube 2 (1 to
4 mm) and the filter (,1 mm) for each patient, ordered from minimum
to maximum. The particles collected in tube 2 and on the filter are
respirable (able to reach the alveolar region).
doi:10.1371/journal.pone.0015100.g002
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through each NIOSH sampler was set to 3.5 liters/minute with a
flow calibrator (Model 4143, TSI) before use. The SKC
BioSampler collects aerosols into 5 ml of universal transport
media (UTM; Copan Diagnostics) at 12.5 liters/minute.
Before each collection, the system was purged and the piston
spirometer was partially filled with 5 liters of clean dry air. The
subject was then asked to sit in front of the system, inhale, exhale,
inhale as deeply as possible, seal their mouth around the
mouthpiece, and cough into the machine using as much of the
air in their lungs as possible. After each cough, the system valve
was closed and the cough-generated aerosol was collected using
the aerosol sampler. This procedure was repeated twice for a total
of three coughs from each subject.
After collection, the nasopharyngeal swabs were immersed in
1 ml UTM in a storage tube. For the NIOSH samplers, 1 ml of
UTM was added to each sampler tube, while the sampler filters
were immersed in 1 ml UTM in a 50 ml centrifuge tube. For the
SKC sampler, the UTM collection media was removed from the
sampler and placed a storage tube. All tubes were vortexed
thoroughly. 500 ml of UTM was then drawn from each tube and
mixed with 500 ml of Lysis/Binding Solution Concentrate (LBSC;
Ambion) in fresh tubes. The tubes with the remaining UTM were
stored overnight at 4uC, while the tubes with UTM and LBSC
were stored overnight at 220uC. In some cases, UTM was not
used; instead, 500 ml of LBSC was added directly to each tube,
and the tubes were stored overnight at 220uC.
To extract the sample RNA, tubes containing samples in LBSC
were thawed, carrier RNA (Ambion) was added to enhance RNA
extraction and XenoRNA (Applied Biosystems) was added as a
qPCR internal control. Total RNA was extracted as previously
reported [6] and immediately transcribed into cDNA using High
Capacity RNA to cDNA Master Mix (Applied Biosystems).
Real-time quantitative PCR was performed with a Model 7500
Fast Real-Time PCR system (Applied Biosystems) using influenza
A matrix-specific primers and probe (Spackman, 2002).
To determine the relative genome copy from seasonal influenza
A-positive aerosol samples, a standard curve was generated from
10-fold serial dilutions of the influenza M1 matrix gene and
analyzed alongside all qPCR reactions. All reactions were run in
duplicate. A negative control without template was included in all
real-time PCR reactions. Real-time PCR detection of the
XenoRNA internal control was performed using the XenoRNA
Control TaqMan Gene Expression Assay from the TaqMan Cells
to Ct Control Kit (Applied Biosystems). The internal controls were
amplified in all samples.
For the viral plaque assay (VPA), Madin Darby canine kidney
(MDCK) cells (CCL-34) were purchased from the American Type
Culture Collection (ATCC, Manassas, VA). Cells were propagated
and maintained in 75-cm
2 flasks (Corning CellBind Surface,
Corning, NY). Growth medium for MDCK cells consisted of
Eagle’s minimal essential medium (EMEM, ATCC) supplemented
with 10% fetal bovine serum (Hyclone Laboratories, Inc, Logan,
Utah), 0.4 units/ml penicillin (Invitrogen, Carlsbad, CA), and
Table 2. Viral plaque assay results for cough-generated aerosols.
Aerosol sampler
Total # of subjects for
whom VPA was performed
on cough aerosol
Total # of these subjects
who were influenza-
positive (by qPCR or VPA)
# of influenza-
positive nasal swabs
# of influenza-
positive cough aerosols
qPCR VPA qPCR VPA
NIOSH two-stage sampler 20 12 9 (of 18) 7 8 1
SKC BioSampler 10 9 9 4 6 1
Nasopharyngeal swabs and cough aerosol samples from 30 subjects were cultured for viable influenza virus. This table shows the number of samples foundt ob e
influenza-positive by qPCR and VPA.
doi:10.1371/journal.pone.0015100.t002
Table 3. Clinical presentation of study participants.
Influenza-positive Influenza-negative
# of subjects 47 11
Oral temperature (uC) 37.4 (SD 0.7) 37.1 (SD 0.4)
Days of symptoms (median) 2 (SD 5) 4 (SD 4)
% of subjects reporting:
Fever/chills 81% 27%
Headache 81% 45%
Fatigue 74% 45%
Cough 85% 55%
Sore throat 87% 18%
Muscle aches 77% 36%
Cough volume (liters) 2.7 (SD 1.1) 3.1 (SD 1.3)
Cough peak expiratory flow rate (liters/minute) 426 (SD 163) 454 (SD 194)
Average values are given, except for days of symptoms, for which the median is shown.
doi:10.1371/journal.pone.0015100.t003
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in a humidified 5% CO2 incubator until about 90% confluent.
The VPA was performed by trypsinizing, washing and plating
MDCK cells at a density of 2.0610
6 per well (CoStar 6-well tissue
culture plate, Corning). Cells were incubated at 35uCi na
humidified 5% CO2 incubator overnight. Confluent cellular
monolayers were next washed two times with PBS (Invitrogen)
and treated with the clinical samples. Following 45 min of
adsorption, virus-infected MDCK cells were washed with
phosphate buffered saline (PBS, Gibco), overlaid with an agarose
medium solution and incubated at 35uC in a humidified 5% CO2
incubator for 48 h. Plaques were visually enumerated and plaque
forming units (PFU)/ml were calculated.
Initially, VPA’s were performed only on nasopharyngeal swabs
and cough aerosols from subjects with positive rapid influenza
tests. After a few days, our preliminary results indicated that the
rapid tests had a lower-than-expected sensitivity, and we changed
our methodology to perform VPA’s on all samples.
Supporting Information
Results S1 Complete set of experimental results for this study.
(TXT)
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Figure 3. Cough aerosol particle collection system. Before each
test, the piston spirometer was purged and partially filled with 5 liters of
clean dry air. When the patient coughed into the system mouthpiece,
the cough flowed through an ultrasonic spirometer which measured
the cough volume and flow rate. The cough then flowed through a
valve and into the piston spirometer, displacing the piston to the right.
When the subject finished coughing, the valve was closed and the
aerosol sampler was turned on. The cough aerosol was pulled out of
the spirometer and collected by the aerosol sampler. As the aerosol
sampler drew air, the piston moved to the left until no air remained in
the spirometer.
doi:10.1371/journal.pone.0015100.g003
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